Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294343749> ?p ?o ?g. }
- W4294343749 endingPage "4265" @default.
- W4294343749 startingPage "4265" @default.
- W4294343749 abstract "Background: The pancreatic ductal adenocarcinoma (PDAC) microenvironment is highly fibrotic and hypoxic, with poor immune cell infiltration. Recently, we showed that nucleolin (NCL) inhibition normalizes tumour vessels and impairs PDAC growth. Methods: Immunocompetent mouse models of PDAC were treated by the pseudopeptide N6L, which selectively inhibits NCL. Tumour-infiltrating immune cells and changes in the tumour microenvironment were analysed. Results: N6L reduced the proportion of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) and increased tumour-infiltrated T lymphocytes (TILs) with an activated phenotype. Low-dose anti-VEGFR2 treatment normalized PDAC vessels but did not modulate the immune suppressive microenvironment. RNAseq analysis of N6L-treated PDAC tumours revealed a reduction of cancer-associated fibroblast (CAF) expansion in vivo and in vitro. Notably, N6L treatment decreased IL-6 levels both in tumour tissues and in serum. Treating mPDAC by an antibody blocking IL-6 reduced the proportion of Tregs and MDSCs and increased the amount of TILs, thus mimicking the effects of N6L. Conclusions: These results demonstrate that NCL inhibition blocks the amplification of lymphoid and myeloid immunosuppressive cells and promotes T cell activation in PDAC through a new mechanism of action dependent on the direct inhibition of the tumoral stroma." @default.
- W4294343749 created "2022-09-02" @default.
- W4294343749 creator A5000354383 @default.
- W4294343749 creator A5004783084 @default.
- W4294343749 creator A5010060790 @default.
- W4294343749 creator A5012996331 @default.
- W4294343749 creator A5014995390 @default.
- W4294343749 creator A5019018273 @default.
- W4294343749 creator A5019406794 @default.
- W4294343749 creator A5020097591 @default.
- W4294343749 creator A5020893157 @default.
- W4294343749 creator A5030107635 @default.
- W4294343749 creator A5034381732 @default.
- W4294343749 creator A5047785825 @default.
- W4294343749 creator A5049901490 @default.
- W4294343749 creator A5051102653 @default.
- W4294343749 creator A5058757303 @default.
- W4294343749 creator A5063835507 @default.
- W4294343749 creator A5074173045 @default.
- W4294343749 creator A5074330370 @default.
- W4294343749 creator A5078518284 @default.
- W4294343749 creator A5078629731 @default.
- W4294343749 creator A5079905701 @default.
- W4294343749 creator A5083560840 @default.
- W4294343749 date "2022-08-31" @default.
- W4294343749 modified "2023-10-18" @default.
- W4294343749 title "Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression" @default.
- W4294343749 cites W1497915798 @default.
- W4294343749 cites W1926642623 @default.
- W4294343749 cites W1988226150 @default.
- W4294343749 cites W1997944395 @default.
- W4294343749 cites W2006202974 @default.
- W4294343749 cites W2043991982 @default.
- W4294343749 cites W2053449864 @default.
- W4294343749 cites W2059836914 @default.
- W4294343749 cites W2064777995 @default.
- W4294343749 cites W2067384676 @default.
- W4294343749 cites W2071462987 @default.
- W4294343749 cites W2079548788 @default.
- W4294343749 cites W2086056107 @default.
- W4294343749 cites W2093608608 @default.
- W4294343749 cites W2100519108 @default.
- W4294343749 cites W2111895881 @default.
- W4294343749 cites W2118971021 @default.
- W4294343749 cites W2123149440 @default.
- W4294343749 cites W2130389715 @default.
- W4294343749 cites W2131783235 @default.
- W4294343749 cites W2153243639 @default.
- W4294343749 cites W2157612047 @default.
- W4294343749 cites W2163890187 @default.
- W4294343749 cites W2166760323 @default.
- W4294343749 cites W2376800108 @default.
- W4294343749 cites W2461513545 @default.
- W4294343749 cites W2533508881 @default.
- W4294343749 cites W2537220355 @default.
- W4294343749 cites W2539381937 @default.
- W4294343749 cites W2559117153 @default.
- W4294343749 cites W2559152251 @default.
- W4294343749 cites W2564665116 @default.
- W4294343749 cites W2605792367 @default.
- W4294343749 cites W2606765235 @default.
- W4294343749 cites W2737822227 @default.
- W4294343749 cites W2757417448 @default.
- W4294343749 cites W2760622450 @default.
- W4294343749 cites W2763924466 @default.
- W4294343749 cites W2765414338 @default.
- W4294343749 cites W2798728508 @default.
- W4294343749 cites W2802851196 @default.
- W4294343749 cites W2804259007 @default.
- W4294343749 cites W2885738414 @default.
- W4294343749 cites W2889433609 @default.
- W4294343749 cites W2889646458 @default.
- W4294343749 cites W2905888775 @default.
- W4294343749 cites W2913153613 @default.
- W4294343749 cites W2955530789 @default.
- W4294343749 cites W2989544844 @default.
- W4294343749 cites W2995903778 @default.
- W4294343749 cites W2996416715 @default.
- W4294343749 cites W3003058300 @default.
- W4294343749 cites W3005674612 @default.
- W4294343749 cites W3009903374 @default.
- W4294343749 cites W3010069459 @default.
- W4294343749 cites W3023998523 @default.
- W4294343749 cites W3122969764 @default.
- W4294343749 cites W3136861954 @default.
- W4294343749 cites W3166071603 @default.
- W4294343749 cites W3168119119 @default.
- W4294343749 cites W3178542415 @default.
- W4294343749 cites W4200423807 @default.
- W4294343749 doi "https://doi.org/10.3390/cancers14174265" @default.
- W4294343749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36077801" @default.
- W4294343749 hasPublicationYear "2022" @default.
- W4294343749 type Work @default.
- W4294343749 citedByCount "3" @default.
- W4294343749 countsByYear W42943437492022 @default.
- W4294343749 countsByYear W42943437492023 @default.
- W4294343749 crossrefType "journal-article" @default.
- W4294343749 hasAuthorship W4294343749A5000354383 @default.